NIMS, in joint research with the University of Tokyo, AIST, the University of Osaka, and Tohoku University, have proposed a ...

Honor is pitching the Magic8 Lite as a practical and affordable camera with long battery life and a robust design. How does ...

Researchers have developed a fiber neural network system that performs intelligent processing of optical communication signals directly in the light domain. This approach integrates optical ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ...

Sanofi’s Wayrilz, the first BTK inhibitor to treat immune thrombocytopenia gets European approval: Paris Saturday, December 27, 2025, 12:00 Hrs [IST] Sanofi, an R&D driven, AI-p ...

Fluoride remains the cornerstone of preventive dentistry, and researchers have analyzed the many delivery methods of fluoride ...

Exercise, weight management and physiotherapy are common approaches recommended by medics, to help treat arthritis, but it is ...

LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered immune-tolerance-restoring therapies, announced today that the first patient ...

Explore some of the best MIDI keyboards on Amazon for beginners, studio work, and live performances. Choose from compact ...

What if tomorrow's chocolate no longer came from cocoa? Faced with global warming and diseases threatening plantations, the ...

Learn more about whether Protagonist Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no ...